Medicus Pharma Ltd.
Nasdaq: MDCXPharmaceutical Preparations · Entity-resolved by Clous
CIK0001997296
TickerMDCX
ExchangeNasdaq
SIC2834
StateA6
FY end12-31
Key financials
Revenue
—
—
Net IncomeFY2025-12-31
-$47.28M
-323.8% YoY
Total AssetsFY2025-12-31
$10.06M
+78.2% YoY
EquityFY2025-12-31
-$67.55K
—
Shares OutstandingFY2025-12-31
41.82M
—
Operating Cash FlowFY2025-12-31
-$22.78M
-122.3% YoY
Market
Market
MDCXClose price
$0.46
Market cap
$25.92M
delayed EOD · as of 2026-06-18
Short interest & fails
Cost to borrow10.10%1.9M shares availablehard to borrow
Short-sale volume
FINRA Reg SHO · daily58.1%
short of total volume · 2026-06-18
2026-06-1858.1%
2026-06-1746.7%
2026-06-1648.9%
2026-06-1547.5%
2026-06-1248.6%
Fails-to-deliver
SEC CNS fails · semi-monthly198.9K
shares failed · 2026-05-29
2026-05-29198.9K sh$0.33
2026-05-2833.3K sh$0.31
2026-05-26167 sh$0.30
2026-05-221.17K sh$0.29
2026-05-2160.16K sh$0.29
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
Medicus Pharma filed Amendment No. 1 to its 2025 Form 10‑K to add the previously omitted Part III information.
What it means
The amendment restores SEC compliance but does not indicate any new financial or operational changes.
What to watch
Watch the forthcoming complete 10‑K (including Part III) for any material disclosures and future filing accuracy.
Generated from public filings · not investment advice
| Concept | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|
| Net Income | -$11.16M | -$47.28M | -323.8% | — |
| Total Assets | $5.65M | $10.06M | +78.2% | — |
| Equity | — | -$67.55K | — | — |
| Operating Cash Flow | -$10.25M | -$22.78M | -122.3% | — |
| Shares Outstanding | — | 41.82M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001997296